FluxMPS™ Minimum Essential Medium (MEM), High Glucose & 25mM HEPES w/o L-Glutamine, Sodium Pyruvate, Sodium Bicarbonate, Phenol Red: 1X Liquid

FluxMPS™ Minimum Essential Medium (MEM), High Glucose & 25mM HEPES w/o L-Glutamine, Sodium Pyruvate, Sodium Bicarbonate, Phenol Red: 1X Liquid

FluxMPS™ Minimum Essential Medium (MEM), High Glucose & 25mM HEPES w/o L-Glutamine, Sodium Pyruvate, Sodium Bicarbonate, Phenol Red: 1X Liquid is a Microfluidics Suitable, ultra-filtered cell culture medium engineered for organ-on-a-chip (OoC), tissue-on-a-chip (ToC), and microphysiological system (MPS) applications. A quadruple-stage train (0.1 µm ×2 + 0.04 µm ×2) reaches a 0.04 µm final cut-off, five times finer than the 0.22 µm membranes used for conventional sterile filtration.

• MEM base with 1 g/L (1000 mg/L) glucose and 25 mM HEPES buffering; formulated without L-glutamine, sodium pyruvate, sodium bicarbonate, and phenol red for maximal downstream formulation control
• Quadruple-stage filtration train (0.1 µm → 0.04 µm → 0.1 µm → 0.04 µm), a 0.04 µm final cut-off — Microfluidics Suitable for OoC/MPS channel geometries
• Endotoxin release specification < 0.05 EU/mL (LAL assay, USP <85> BET), controlled and tested per manufacturing batch
• HEPES-buffered, sodium-bicarbonate-free formulation reduces CO₂ incubator dependence
• Phenol-red-free and bicarbonate-free base is compatible with optical assays and Agilent Seahorse XF workflows
• Prepared with Ultrapure Type 1 water (18.2 MΩ·cm); ISO Class 5 aseptic fill & finish under an ISO 13485:2016 QMS
• Final QC and release performed at Diagnocine, Totowa, NJ, with full lot traceability and CoA on request
• Custom formulations available — pH, glucose, salts, HEPES, and nutrient composition on request

Engineered where standard media fails

Conventional 0.22 µm-filtered media carry mycoplasma-sized particulates (0.2–0.3 µm), subvisible debris, and batch-to-batch endotoxin variation that accumulate inside microchannels — corrupting biosensor readings, triggering inflammation in primary cultures, and shortening device lifetimes. FluxMPS™ is built to reduce these failure modes at the source.

Quadruple-stage filtration system

FluxMPS™ Minimum Essential Medium (MEM), High Glucose & 25mM HEPES w/o L-Glutamine, Sodium Pyruvate, Sodium Bicarbonate, Phenol Red: 1X Liquid is processed through a four-stage serial filtration sequence — two dedicated prefilter/final-filter pairs — reaching a 0.04 µm final cut-off, addressing mycoplasma-sized organisms and subvisible particulates that 0.22 µm filtration cannot address.

1. 1

   0.1 µm Prefiltration I

   Removes large particulates, cell debris, and protein aggregates; protects the first 0.04 µm final-filter cartridge.

2. 2

   0.04 µm Final filtration I

   First 0.04 µm pass; retains organisms in the mycoplasma size range (0.2–0.3 µm) and sub-micron particulates that pass a 0.22 µm filter.

3. 3

   0.1 µm Prefiltration II

   Second dedicated prefilter, protecting the second 0.04 µm final-filter cartridge from residual load.

4. 4

   0.04 µm Final filtration II — Polish

   Ultimate polishing filter; ISO Class 5 aseptic fill performed in a validated laminar-flow workstation.

Designed for next-generation cell culture platforms

FluxMPS™ Minimum Essential Medium (MEM), High Glucose & 25mM HEPES w/o L-Glutamine, Sodium Pyruvate, Sodium Bicarbonate, Phenol Red: 1X Liquid is validated for organ-on-a-chip, cancer biology, metabolic research, live-cell imaging, and primary cell models where particulate contamination and endotoxin variation are unacceptable.

Automated Bioreactors & Robotics

An optional 0.01 µm (10 nm) ultra nano-filtered MPS Grade variant — a distinct product line from this Microfluidics Suitable medium — is available for automated bioreactor and robotic perfusion systems requiring the ultimate particulate exclusion.

• Total Particulate Exclusion: 10 nm filtration for nanoscale valve and sensor protection
• Valve & Sensor Protection: prevents particulate-induced blockage in precision fluidic systems
• Extended Perfusion Stability: maintains flow rate consistency across multi-week automated runs

Inquiry Required: Contact support@diagnocine.com to request the 0.01 µm MPS Grade variant.

Lot-release quality parameters

Every production lot of FluxMPS™ Minimum Essential Medium (MEM), High Glucose & 25mM HEPES w/o L-Glutamine, Sodium Pyruvate, Sodium Bicarbonate, Phenol Red: 1X Liquid undergoes the complete quality-release battery below before shipment.

Full composition (mg/L)

Complete formulation with CAS numbers, reproduced from manufacturer specification. Custom compositions available on request.

ISO 13485:2016 manufacturing & compliance

Manufactured under ISO 13485:2016 QMS with final packaging, testing, and customization at Diagnocine Precision in Totowa, New Jersey, USA.

How DCP-MEMGH-QPBRN1X (FluxMPS™) compares

Side-by-side comparison against conventional 0.22 µm-filtered MEM High Glucose alternatives, and a sourced comparison of published endotoxin specifications.

Comparison figures from published supplier specifications, accessed 2026-09-02. Suppliers that publish no numeric endotoxin specification are shown as "Not specified".

Frequently asked questions

Common questions about FluxMPS™ Minimum Essential Medium (MEM), High Glucose & 25mM HEPES w/o L-Glutamine, Sodium Pyruvate, Sodium Bicarbonate, Phenol Red: 1X Liquid and Microfluidics Suitable cell culture media.

Supporting literature

Peer-reviewed publications supporting Microfluidics Suitable, ultra-filtered media and microfluidic cell culture applications.

1. Huh D et al. (2010). Reconstituting organ-level lung functions on a chip. Science, 328(5986), 1662–1668. doi:10.1126/science.1188302
2. Bhatia SN & Ingber DE (2014). Microfluidic organs-on-chips. Nature Biotechnology, 32(8), 760–772. doi:10.1038/nbt.2989
3. Eagle H (1959). Amino acid metabolism in mammalian cell cultures. Science, 130(3373), 432–437. doi:10.1126/science.130.3373.432
4. Warburg O (1956). On the origin of cancer cells. Science, 123(3191), 309–314. doi:10.1126/science.123.3191.309
5. Bhattacharya S et al. (2018). Challenges in maintaining cell viability during microfluidic experiments. Electrophoresis, 39(7), 997–1006. doi:10.1002/elps.201700375
6. Zhang YS et al. (2017). Multisensor-integrated organs-on-chips for automated in situ monitoring. PNAS, 114(12), E2293–E2302. doi:10.1073/pnas.1612906114
7. Vernetti L et al. (2017). Functional coupling of human microphysiology systems. Scientific Reports, 7, 42296. doi:10.1038/srep42296
8. Esch EW et al. (2015). Organs-on-chips at the frontiers of drug discovery. Nature Reviews Drug Discovery, 14(4), 248–260. doi:10.1038/nrd4539
9. Zheng F et al. (2021). Organ-on-a-chip systems: microengineering to biomimic living systems. Small, 17(7), 2004175. doi:10.1002/smll.202004175